How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/msb11456.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MSB11456 — Competitive Intelligence Brief

MSB11456 (MSB11456) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (biosimilar). Area: Oncology.

phase 3 Monoclonal antibody (biosimilar) HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MSB11456 (MSB11456) — Fresenius Kabi SwissBioSim GmbH. MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MSB11456 TARGET	MSB11456	Fresenius Kabi SwissBioSim GmbH	phase 3	Monoclonal antibody (biosimilar)	HER2 (human epidermal growth factor receptor 2)
CT-P17 SC	CT-P17 SC	Celltrion	phase 3	TNF-alpha inhibitor monoclonal antibody (biosimilar)	TNF-alpha
MSB11022	MSB11022	Fresenius Kabi SwissBioSim GmbH	phase 3	Monoclonal antibody (biosimilar)	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (biosimilar) class)

Fresenius Kabi SwissBioSim GmbH · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MSB11456 — Competitive Intelligence Brief. https://druglandscape.com/ci/msb11456. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab